BACKGROUND: Hybrid closed loop (HCL) therapy is now available in clinical practice for treatment of type 1 diabetes; however, there is limited research on how to educate patients on this new therapy. The purpose of this quality improvement project was to optimize a HCL education program for pediatric patients with type 1 diabetes (T1D). METHODS: Our multidisciplinary team developed a novel HCL clinical training program for current insulin pump users, using a quality improvement process called the Plan-Do-Study-Act model. Seventy-two patients participated in the HCL training program, which included (1) an in-person group class to reinforce conventional insulin pump and CGM use on the new system, (2) a live video conference class to teach HCL use, and (3) three follow-up phone calls in the first 4 weeks after HCL training to assess system use, make insulin adjustments, and provide targeted reeducation. Diabetes educators collected data during follow-up calls, and patients completed a training satisfaction survey. RESULTS: The quality improvement process resulted in a training program that emphasized education on HCL exits, CGM use, and optimizing insulin to carbohydrate ratio settings. Patients successfully sustained time in HCL in the initial weeks of use and rated the trainings and follow-up calls highly. CONCLUSIONS: Ongoing educational support is vital in the early weeks of HCL use. This quality improvement project is the first to examine strategies for implementation of HCL therapy into a large pediatric diabetes center, and may inform best practices for implementation of new diabetes technologies into other diabetes clinics.
BACKGROUND: Hybrid closed loop (HCL) therapy is now available in clinical practice for treatment of type 1 diabetes; however, there is limited research on how to educate patients on this new therapy. The purpose of this quality improvement project was to optimize a HCL education program for pediatric patients with type 1 diabetes (T1D). METHODS: Our multidisciplinary team developed a novel HCL clinical training program for current insulin pump users, using a quality improvement process called the Plan-Do-Study-Act model. Seventy-two patients participated in the HCL training program, which included (1) an in-person group class to reinforce conventional insulin pump and CGM use on the new system, (2) a live video conference class to teach HCL use, and (3) three follow-up phone calls in the first 4 weeks after HCL training to assess system use, make insulin adjustments, and provide targeted reeducation. Diabetes educators collected data during follow-up calls, and patients completed a training satisfaction survey. RESULTS: The quality improvement process resulted in a training program that emphasized education on HCL exits, CGM use, and optimizing insulin to carbohydrate ratio settings. Patients successfully sustained time in HCL in the initial weeks of use and rated the trainings and follow-up calls highly. CONCLUSIONS: Ongoing educational support is vital in the early weeks of HCL use. This quality improvement project is the first to examine strategies for implementation of HCL therapy into a large pediatric diabetes center, and may inform best practices for implementation of new diabetes technologies into other diabetes clinics.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Boris Kovatchev; Peiyao Cheng; Stacey M Anderson; Jordan E Pinsker; Federico Boscari; Bruce A Buckingham; Francis J Doyle; Korey K Hood; Sue A Brown; Marc D Breton; Daniel Chernavvsky; Wendy C Bevier; Paige K Bradley; Daniela Bruttomesso; Simone Del Favero; Roberta Calore; Claudio Cobelli; Angelo Avogaro; Trang T Ly; Satya Shanmugham; Eyal Dassau; Craig Kollman; John W Lum; Roy W Beck Journal: Diabetes Technol Ther Date: 2016-12-16 Impact factor: 6.118
Authors: Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover Journal: Diabetes Care Date: 2018-02-14 Impact factor: 19.112
Authors: Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2017-01-30 Impact factor: 6.118
Authors: Martin Tauschmann; Janet M Allen; Malgorzata E Wilinska; Hood Thabit; Zoë Stewart; Peiyao Cheng; Craig Kollman; Carlo L Acerini; David B Dunger; Roman Hovorka Journal: Diabetes Care Date: 2016-01-06 Impact factor: 19.112
Authors: Trang T Ly; Marc D Breton; Patrick Keith-Hynes; Daniel De Salvo; Paula Clinton; Kari Benassi; Benton Mize; Daniel Chernavvsky; Jéróme Place; Darrell M Wilson; Boris P Kovatchev; Bruce A Buckingham Journal: Diabetes Care Date: 2014-05-30 Impact factor: 19.112
Authors: Molly L Tanenbaum; Laurel H Messer; Christine A Wu; Marina Basina; Bruce A Buckingham; Danielle Hessler; Shelagh A Mulvaney; David M Maahs; Korey K Hood Journal: Diabetes Res Clin Pract Date: 2021-09-14 Impact factor: 8.180
Authors: Gregory P Forlenza; Tim Vigers; Cari Berget; Laurel H Messer; Rayhan A Lal; Marina Basina; David M Maahs; Korey Hood; Bruce Buckingham; Darrell M Wilson; R Paul Wadwa; Kimberly A Driscoll; Laura Pyle Journal: Diabetes Technol Ther Date: 2021-12-01 Impact factor: 7.337
Authors: Cari Berget; Laurel H Messer; Tim Vigers; Brigitte I Frohnert; Laura Pyle; R Paul Wadwa; Kimberly A Driscoll; Gregory P Forlenza Journal: Pediatr Diabetes Date: 2020-01-07 Impact factor: 4.866
Authors: Laurel H Messer; Cari Berget; Tim Vigers; Laura Pyle; Cristy Geno; R Paul Wadwa; Kimberly A Driscoll; Gregory P Forlenza Journal: Pediatr Diabetes Date: 2020-01-03 Impact factor: 4.866
Authors: Laurel H Messer; Cari Berget; Ashlee Ernst; Lindsey Towers; Robert H Slover; Gregory P Forlenza Journal: Pediatr Diabetes Date: 2021-03-16 Impact factor: 4.866